Angiotensin Converting Enzyme Inhibition in Plasma and Tissues
Autor: | Bruce Jackson, Colin I. Johnston, R B Cubela, Keiji Sakaguchi |
---|---|
Rok vydání: | 1987 |
Předmět: |
medicine.medical_specialty
Renal function Angiotensin-Converting Enzyme Inhibitors Peptidyl-Dipeptidase A Pharmacology Kidney Function Tests Enalapril Pharmacokinetics Lisinopril Internal medicine Renin–angiotensin system Internal Medicine medicine Animals Humans biology Chemistry Radioimmunoassay Angiotensin-converting enzyme Dipeptides Rats Kinetics Endocrinology Pharmacodynamics ACE inhibitor biology.protein Kidney Failure Chronic Protein Binding circulatory and respiratory physiology medicine.drug |
Zdroj: | Clinical and Experimental Hypertension. Part A: Theory and Practice. 9:307-321 |
ISSN: | 0730-0077 |
Popis: | Angiotensin converting enzyme (ACE) and the ACE inhibitor lisinopril were measured in patients with renal impairment, by both radioinhibitor 125I MK351A binding studies, and by radioimmunoassay. Plasma concentration of lisinopril estimated by radioinhibitor binding displacement correlated closely with that measured by radioimmunoassay. Plateau lisinopril concentration in 8 patients with varying degrees of renal failure treated with 5 mg lisinopril per day for 1 week, was inversely related to renal function. Plasma lisinopril concentrations of 30-70 ng/ml were required for 50% inhibition of plasma ACE activity in vivo. Acute studies in the rat showed inhibition of ACE in different tissues had different time courses. These observations suggest that 125I MK351A binding studies in tissues will be useful in establishing the pharmacokinetic and pharmacodynamic profiles of newer ACE inhibitors, and may help delineate the contribution of ACE in different tissues to cardiovascular homeostasis. |
Databáze: | OpenAIRE |
Externí odkaz: |